Cargando…

Novel cholesterol‐dependent regulation of cardiac K(ATP) subunit expression revealed using histone deacetylase inhibitors

We recently discovered that the histone deacetylase inhibitor, trichostatin A (TSA), increases expression of the sulfonylurea receptor 2 (SUR2; Abcc9) subunit of the ATP‐sensitive K(+) (K(ATP)) channel in HL‐1 cardiomyocytes. Interestingly, the increase in SUR2 was abolished with exogenous cholester...

Descripción completa

Detalles Bibliográficos
Autores principales:	Geiger, Robert, Fatima, Naheed, Schooley, James F., Smyth, Jeremy T., Haigney, Mark C., Flagg, Thomas P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7757372/ https://www.ncbi.nlm.nih.gov/pubmed/33356020 http://dx.doi.org/10.14814/phy2.14675

Ejemplares similares

Histone deacetylase inhibitors modulate K(ATP) subunit transcription in HL-1 cardiomyocytes through effects on cholesterol homeostasis
por: Fatima, Naheed, et al.
Publicado: (2015)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Methadone Blockade of Cardiac Inward Rectifier K(+) Current Augments Membrane Instability and Amplifies U Waves on Surface ECGs: A Translational Study
por: Klein, Michael G., et al.
Publicado: (2022)

Histone deacetylase inhibitors: A new mode for inhibition of cholesterol metabolism
por: Chittur, Sridar V, et al.
Publicado: (2008)

Rapid Assessment of Proarrhythmic Potential Using Human iPSC-Derived Cardiomyocytes
por: Geiger, Robert M., et al.
Publicado: (2020)

Promoter DNA Methylation Regulates Murine SUR1 (Abcc8) and SUR2 (Abcc9) Expression in HL-1 Cardiomyocytes
por: Fatima, Naheed, et al.
Publicado: (2012)

Mechanism of histone deacetylases in cardiac hypertrophy and its therapeutic inhibitors
por: Han, Yu, et al.
Publicado: (2022)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Histone deacetylase inhibitors in multiple myeloma
por: Deleu, Sarah, et al.
Publicado: (2009)

Histone deacetylase inhibitors in Hodgkin lymphoma
por: Buglio, Daniela, et al.
Publicado: (2010)

Clinical Toxicities of Histone Deacetylase Inhibitors
por: Subramanian, Srividya, et al.
Publicado: (2010)

Acetylation and Histone Deacetylase Inhibitors in Cancer
por: Kortenhorst, Madeleine S. Q., et al.
Publicado: (2006)

Histone Deacetylase Inhibitors as Anticancer Drugs
por: Eckschlager, Tomas, et al.
Publicado: (2017)

The application of histone deacetylases inhibitors in glioblastoma
por: Chen, Rui, et al.
Publicado: (2020)

Histone Deacetylases and Their Inhibitors in Cancer Epigenetics
por: Hassell, Kelly N.
Publicado: (2019)

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
por: Yan, Wensheng, et al.
Publicado: (2012)

Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors
por: Lapierre, Marion, et al.
Publicado: (2016)

Histone deacetylase 3 represses cholesterol efflux during CD4(+) T-cell activation
por: Wilfahrt, Drew, et al.
Publicado: (2021)

Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma
por: Yelton, Caleb J., et al.
Publicado: (2018)

Histone deacetylase inhibitors as novel anticancer therapeutics
por: Walkinshaw, D.R., et al.
Publicado: (2008)

Regulation of Immune Responses by Histone Deacetylase Inhibitors
por: Licciardi, Paul V., et al.
Publicado: (2012)

Interpreting clinical assays for histone deacetylase inhibitors
por: Martinet, Nadine, et al.
Publicado: (2011)

Myelodysplastic Syndrome and Histone Deacetylase Inhibitors: “To Be or Not to Be Acetylated”?
por: Stintzing, Sebastian, et al.
Publicado: (2011)

Overview of Histone Deacetylase Inhibitors in Haematological Malignancies
por: Bishton, Mark J., et al.
Publicado: (2010)

Dual Inhibitors Against Topoisomerases and Histone Deacetylases
por: Seo, Young Ho
Publicado: (2015)

Attenuation of Choroidal Neovascularization by Histone Deacetylase Inhibitor
por: Chan, Nymph, et al.
Publicado: (2015)

Zinc binding groups for histone deacetylase inhibitors
por: Zhang, Lei, et al.
Publicado: (2018)

The effect of histone deacetylase inhibitors on AHSP expression
por: Okhovat, Mohammad Ali, et al.
Publicado: (2018)

Histone Deacetylase Inhibitors and Diabetic Kidney Disease
por: Hadden, Mitchell J., et al.
Publicado: (2018)

The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy
por: Li, Guo, et al.
Publicado: (2020)

Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy
por: Verza, Flávia Alves, et al.
Publicado: (2020)

Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis
por: Ghazy, Ehab, et al.
Publicado: (2022)

Next-generation of selective histone deacetylase inhibitors
por: Yang, Feifei, et al.
Publicado: (2019)

Histone Deacetylase Inhibitors from Marine Invertebrates
por: Luparello, Claudio, et al.
Publicado: (2020)

Antitheilerial Activity of the Anticancer Histone Deacetylase Inhibitors
por: Barman, Madhumanti, et al.
Publicado: (2021)

The Impact of Fluorination on the Design of Histone Deacetylase Inhibitors
por: Tien Anh, Duong, et al.
Publicado: (2023)

The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects
por: West, Alison C., et al.
Publicado: (2012)

Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer
por: Alzoubi, Samer, et al.
Publicado: (2016)

Statins and Histone Deacetylase Inhibitors Affect Lamin A/C – Histone Deacetylase 2 Interaction in Human Cells
por: Mattioli, Elisabetta, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ukiiie31h04hv57dh98negrp77